5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Europe Clinical Trials Market is segmented by Phase (Phase I, II, III, and IV), Design, and Geography.
2018 - 2026
Factors that are responsible for the growth of the European clinical trials market include high R&D spending of the pharmaceutical industry and the increasing prevalence of diseases.
Clinical trials are the experiments conducted in clinical research, and they follow a regulated protocol. They are performed particularly to obtain data on safety and efficacy of a newly developed drug. Clinical trial data is mandatory for further approval of the drug, for it to enter the market.
Report scope can be customized per your requirements. Click here.
Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice. As per the EU Clinical Trials Register, a total number of 12,748 studies are currently in Phase III trials in European countries.
In phase III, the drug or the treatment is tested in large groups of people, ranging from 1,000 to 3,000 participants. These trials are conducted to confirm and expand on the safety and effectiveness results from Phase I and II trials, to compare the drug to standard therapies for the disease or condition being studied, and to evaluate the overall risks and benefits of the drug.
To understand key trends, Download Sample Report
The European clinical trials market is competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising need for new drugs and treatments, advances in healthcare, and an increasing number of new diseases, it is expected that few smaller players will enter the market and may hold a substantial share in the near future. Some of the major players of the market are Eli Lilly and Company, Pfizer Inc., Pharmaceutical Product Development LLC, Novo Nordisk, and Sanofi, among others.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High R&D Spending of the Pharmaceutical Industry
4.2.2 Increasing Prevalence of Diseases
4.2.3 Focus on Rare Diseases and Multiple Orphan Drugs in Pipeline
4.3 Market Restraints
4.3.1 Lower Healthcare Reimbursement in Developing Countries
4.3.2 Stringent Regulations for Patient Enrollment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Design
5.2.1 Treatment Studies
126.96.36.199 Randomized Control Trial
188.8.131.52 Adaptive Clinical Trial
184.108.40.206 Non-randomized Control Trial
5.2.2 Observational Studies
220.127.116.11 Cohort Study
18.104.22.168 Case Control Study
22.214.171.124 Cross Sectional Study
126.96.36.199 Ecological Study
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Clinipace Worldwide
6.1.2 Eli Lilly and Company
6.1.3 ICON PLC
6.1.4 Novo Nordisk
6.1.6 Pfizer Inc.
6.1.7 Pharmaceutical Product Development LLC
6.1.9 F. Hoffmann-La Roche AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments